About Sera Prognostics
Sera Prognostics is a company based in Salt Lake City (United States) founded in 2008. It operates as a HealthTech. The company has 123 employees as of December 31, 2021. Sera Prognostics offers products and services including PreTRM Test and LikeMine Platform. Sera Prognostics operates in a competitive market with competitors including Mirvie, Pregnolia, Yourgene Health, NX Prenatal and Rea Diagnostics, among others.
- Headquarter Salt Lake City, United States
- Employees 123 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sera Prognostics
-
Annual Revenue
$268 K (USD)0as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
123
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sera Prognostics
Sera Prognostics is a publicly listed company on the NASDAQ with ticker symbol SERA in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Sera Prognostics
Sera Prognostics offers a comprehensive portfolio of products and services, including PreTRM Test and LikeMine Platform.
Risk of preterm delivery is predicted through blood test.
Pregnancy outcomes are compared using extensive U.S. data.
People of Sera Prognostics
Unlock access to complete
Funding Insights of Sera Prognostics
Detailed funding history for Sera Prognostics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sera Prognostics
Investment portfolio details for Sera Prognostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sera Prognostics
Detailed financials for Sera Prognostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sera Prognostics Comparisons
Peer comparison for Sera Prognostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sera Prognostics
Sera Prognostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mirvie, Pregnolia, Yourgene Health, NX Prenatal and Rea Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-invasive blood tests for prenatal fetal health predictions are offered.
|
|
| Locked | Locked | Locked |
Preterm birth risks are predicted using cervical stiffness measurement devices.
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genetic tests and genomic services are provided.
|
|
| Locked | Locked | Locked |
Early warning blood tests for pregnancy complications are provided.
|
|
| Locked | Locked | Locked |
Wearable diagnostic device is provided to monitor preterm birth risks.
|
Detailed competitors of Sera Prognostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sera Prognostics
Complete news archive for Sera Prognostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sera Prognostics
Sera Prognostics was founded in 2008.
Sera Prognostics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
As of Dec 31, 2021, the latest employee count at Sera Prognostics is 123.
Annual revenue of Sera Prognostics is $268K as on Dec 31, 2022.
Sera Prognostics is dedicated to advancing womens health diagnostics with a focus on prenatal care. Solutions are developed to predict risks such as preterm delivery for pregnant women. The company serves healthcare providers, payers, employers, and mothers through innovative tools like the PreTRM Test and LikeMine platform. Research and innovation in maternal biomarkers are emphasized to improve neonatal outcomes and reduce healthcare costs. The healthcare sector, specifically prenatal testing, is the primary area of operation.
Sera Prognostics's top competitors include Mirvie, NX Prenatal and Yourgene Health.
Sera Prognostics offers PreTRM Test and LikeMine Platform.
Yes, Sera Prognostics is publicly traded on NASDAQ under the ticker symbol SERA.
The ticker symbol of Sera Prognostics is SERA on NASDAQ.